Immunotherapy and Cellular Therapies for Cancers in Kidney Transplant Patients.
1/5 보강
[BACKGROUND] Kidney transplant is the treatment of choice for end-stage kidney disease, with longer survival and better quality of life posttransplant.
APA
Merzkani M, Attieh RM, et al. (2026). Immunotherapy and Cellular Therapies for Cancers in Kidney Transplant Patients.. American journal of nephrology, 57(2), 154-167. https://doi.org/10.1159/000544826
MLA
Merzkani M, et al.. "Immunotherapy and Cellular Therapies for Cancers in Kidney Transplant Patients.." American journal of nephrology, vol. 57, no. 2, 2026, pp. 154-167.
PMID
39978323 ↗
Abstract 한글 요약
[BACKGROUND] Kidney transplant is the treatment of choice for end-stage kidney disease, with longer survival and better quality of life posttransplant. However, long-term immunosuppression comes with an increased risk of cancer and infection. Cancer is one of the leading causes of death after kidney transplant. While novel cancer therapies become available, transplant recipients are usually excluded from clinical trials.
[SUMMARY] In this review, we summarize the updated knowledge on immunosuppression management in kidney transplant recipients treated with immune checkpoint inhibitors (ICIs), bispecific T-cell engager therapy, and chimeric antigen receptor (CAR)-T-cell therapies.
[KEY MESSAGES] Transplant nephrologists should be empowered to participate in the decision-making of cancer treatment together with patients, care partners, and oncologists, by managing immunosuppression.
[SUMMARY] In this review, we summarize the updated knowledge on immunosuppression management in kidney transplant recipients treated with immune checkpoint inhibitors (ICIs), bispecific T-cell engager therapy, and chimeric antigen receptor (CAR)-T-cell therapies.
[KEY MESSAGES] Transplant nephrologists should be empowered to participate in the decision-making of cancer treatment together with patients, care partners, and oncologists, by managing immunosuppression.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.